schliessen

Filtern

 

Bibliotheken

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.

The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progre... Full description

Journal Title: Oncotarget December 27, 2016, Vol.7(52), pp.85917-85928
Main Author: Wang, Hsian-Yu
Other Authors: Chang, Yu-Ling , Cheng, Chun-Chun , Chao, Min-Wu , Lin, Su-I , Pan, Shiow-Lin , Hsu, Chih-Cheng , Liu, Tsang-Wu , Cheng, Han-Chin , Tseng, Ching-Ping , Liu, Shih-Jen , Tsai, Hui-Ju , Chang, Hsing-Yi , Hsu, John T-A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.13185
Link: http://search.proquest.com/docview/1839111472/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1839111472
title: Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
format: Article
creator:
  • Wang, Hsian-Yu
  • Chang, Yu-Ling
  • Cheng, Chun-Chun
  • Chao, Min-Wu
  • Lin, Su-I
  • Pan, Shiow-Lin
  • Hsu, Chih-Cheng
  • Liu, Tsang-Wu
  • Cheng, Han-Chin
  • Tseng, Ching-Ping
  • Liu, Shih-Jen
  • Tsai, Hui-Ju
  • Chang, Hsing-Yi
  • Hsu, John T-A
subjects:
  • Adult–Pharmacology
  • Aged–Drug Effects
  • Aged, 80 and Over–Drug Therapy
  • Animals–Mortality
  • Antineoplastic Agents–Antagonists & Inhibitors
  • Apoptosis–Pharmacology
  • Carcinoma, Non-Small-Cell Lung–Drug Therapy
  • Cell Line, Tumor–Mortality
  • Erbb Receptors–Pharmacology
  • Female–Pharmacology
  • Gefitinib–Pharmacology
  • Glucocorticoids–Pharmacology
  • Humans–Pharmacology
  • Lung Neoplasms–Pharmacology
  • Male–Pharmacology
  • Mice–Pharmacology
  • Middle Aged–Pharmacology
  • Quinazolines–Pharmacology
  • Xenograft Model Antitumor Assays
ispartof: Oncotarget, December 27, 2016, Vol.7(52), pp.85917-85928
description: The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.
language: eng
source:
identifier: E-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.13185
fulltext: fulltext
issn:
  • 19492553
  • 1949-2553
url: Link


@attributes
ID563654296
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1839111472
sourceidproquest
recordidTN_proquest1839111472
sourcesystemPC
pqid1839111472
display
typearticle
titleGlucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
creatorWang, Hsian-Yu ; Chang, Yu-Ling ; Cheng, Chun-Chun ; Chao, Min-Wu ; Lin, Su-I ; Pan, Shiow-Lin ; Hsu, Chih-Cheng ; Liu, Tsang-Wu ; Cheng, Han-Chin ; Tseng, Ching-Ping ; Liu, Shih-Jen ; Tsai, Hui-Ju ; Chang, Hsing-Yi ; Hsu, John T-A
contributorWang, Hsian-Yu (correspondence author) ; Wang, Hsian-Yu (record owner)
ispartofOncotarget, December 27, 2016, Vol.7(52), pp.85917-85928
identifierE-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.13185
subjectAdult–Pharmacology ; Aged–Drug Effects ; Aged, 80 and Over–Drug Therapy ; Animals–Mortality ; Antineoplastic Agents–Antagonists & Inhibitors ; Apoptosis–Pharmacology ; Carcinoma, Non-Small-Cell Lung–Drug Therapy ; Cell Line, Tumor–Mortality ; Erbb Receptors–Pharmacology ; Female–Pharmacology ; Gefitinib–Pharmacology ; Glucocorticoids–Pharmacology ; Humans–Pharmacology ; Lung Neoplasms–Pharmacology ; Male–Pharmacology ; Mice–Pharmacology ; Middle Aged–Pharmacology ; Quinazolines–Pharmacology ; Xenograft Model Antitumor Assays
languageeng
source
descriptionThe epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1839111472/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Wang, Hsian-Yu
1Chang, Yu-Ling
2Cheng, Chun-Chun
3Chao, Min-Wu
4Lin, Su-I
5Pan, Shiow-Lin
6Hsu, Chih-Cheng
7Liu, Tsang-Wu
8Cheng, Han-Chin
9Tseng, Ching-Ping
10Liu, Shih-Jen
11Tsai, Hui-Ju
12Chang, Hsing-Yi
13Hsu, John T-A
titleGlucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
subject
0Adult–Pharmacology
1Aged–Drug Effects
2Aged, 80 and Over–Drug Therapy
3Animals–Mortality
4Antineoplastic Agents–Antagonists & Inhibitors
5Apoptosis–Pharmacology
6Carcinoma, Non-Small-Cell Lung–Drug Therapy
7Cell Line, Tumor–Mortality
8Erbb Receptors–Pharmacology
9Female–Pharmacology
10Gefitinib–Pharmacology
11Glucocorticoids–Pharmacology
12Humans–Pharmacology
13Lung Neoplasms–Pharmacology
14Male–Pharmacology
15Mice–Pharmacology
16Middle Aged–Pharmacology
17Quinazolines–Pharmacology
18Xenograft Model Antitumor Assays
19EGFR
20NSCLC
21TKI
22glucocorticoids
23national health insurance research database Taiwan
general
0English
110.18632/oncotarget.13185
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1839111472
issn
019492553
11949-2553
rsrctypearticle
creationdate2016
addtitleOncotarget
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorWang, Hsian-Yu
startdate20161227
enddate20161227
citationpf 85917 pt 85928 vol 7 issue 52
lsr30VSR-Enriched:[description, pqid]
sort
titleGlucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
authorWang, Hsian-Yu ; Chang, Yu-Ling ; Cheng, Chun-Chun ; Chao, Min-Wu ; Lin, Su-I ; Pan, Shiow-Lin ; Hsu, Chih-Cheng ; Liu, Tsang-Wu ; Cheng, Han-Chin ; Tseng, Ching-Ping ; Liu, Shih-Jen ; Tsai, Hui-Ju ; Chang, Hsing-Yi ; Hsu, John T-A
creationdate20161227
lso0120161227
facets
frbrgroupid8833653062292475561
frbrtype5
newrecords20181218
languageeng
creationdate2016
topic
0Adult–Pharmacology
1Aged–Drug Effects
2Aged, 80 and Over–Drug Therapy
3Animals–Mortality
4Antineoplastic Agents–Antagonists & Inhibitors
5Apoptosis–Pharmacology
6Carcinoma, Non-Small-Cell Lung–Drug Therapy
7Cell Line, Tumor–Mortality
8Erbb Receptors–Pharmacology
9Female–Pharmacology
10Gefitinib–Pharmacology
11Glucocorticoids–Pharmacology
12Humans–Pharmacology
13Lung Neoplasms–Pharmacology
14Male–Pharmacology
15Mice–Pharmacology
16Middle Aged–Pharmacology
17Quinazolines–Pharmacology
18Xenograft Model Antitumor Assays
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Hsian-Yu
1Chang, Yu-Ling
2Cheng, Chun-Chun
3Chao, Min-Wu
4Lin, Su-I
5Pan, Shiow-Lin
6Hsu, Chih-Cheng
7Liu, Tsang-Wu
8Cheng, Han-Chin
9Tseng, Ching-Ping
10Liu, Shih-Jen
11Tsai, Hui-Ju
12Chang, Hsing-Yi
13Hsu, John T-A
jtitleOncotarget
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Wang
1Chang
2Cheng
3Chao
4Lin
5Pan
6Hsu
7Liu
8Tseng
9Tsai
aufirst
0Hsian-Yu
1Yu-Ling
2Chun-Chun
3Min-Wu
4Su-I
5Shiow-Lin
6Chih-Cheng
7Tsang-Wu
8Han-Chin
9Ching-Ping
10Shih-Jen
11Hui-Ju
12Hsing-Yi
13John T-A
au
0Wang, Hsian-Yu
1Chang, Yu-Ling
2Cheng, Chun-Chun
3Chao, Min-Wu
4Lin, Su-I
5Pan, Shiow-Lin
6Hsu, Chih-Cheng
7Liu, Tsang-Wu
8Cheng, Han-Chin
9Tseng, Ching-Ping
10Liu, Shih-Jen
11Tsai, Hui-Ju
12Chang, Hsing-Yi
13Hsu, John T-A
addauWang, Hsian-Yu
atitleGlucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
jtitleOncotarget
risdate20161227
volume7
issue52
spage85917
epage85928
pages85917-85928
eissn1949-2553
formatjournal
genrearticle
ristypeJOUR
doi10.18632/oncotarget.13185
urlhttp://search.proquest.com/docview/1839111472/
date2016-12-27